Healthcare Industry News: HSMN NewsFeed
News Release - March 15, 2018
Organogenesis Announces New PuraPly(R) Antimicrobial Small SizeCANTON, Mass., March 15, 2018 -- (Healthcare Sales & Marketing Network) -- Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets, today announced its PuraPly® Antimicrobial (AM) wound management product is now available in a new, easy-to-use 1.6 cm disc size.
"A vast majority of wounds – including small ones – contain biofilm, which represents a serious challenge to wound healing," said Gary S. Gillheeney, Sr., President and CEO of Organogenesis. "The new small size of PuraPly AM – which utilizes PHMB to manage bioburden while supporting healing – gives clinicians an exciting new option for treating a wide range of small wounds."
PuraPly® and PuraPly AM are both FDA 510(k)-cleared Class II medical devices indicated for acute and chronic wound management across a wide variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, and venous and diabetic ulcers. Both products are available in a range of sizes to meet the needs of a variety of wound types.
PuraPly AM utilizes a novel technology—purified native collagen matrix embedded with polyhexamethylene biguanide, or PHMB, a broad-spectrum antimicrobial. This unique combination of native collagen and PHMB helps manage the reformation of biofilm while supporting healing across a wide variety of wound types, regardless of severity or duration.
PuraPly AM has been named one of the "Top 10 Innovations in Podiatry" by Podiatry Today, an award-winning publication that covers the latest developments in podiatric medicine.
About Organogenesis Inc.
Originally founded as a spin-off from technology developed at MIT in 1985, Massachusetts-based Organogenesis Inc. offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.